A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.

MLA

Wong JYC, et al. “A Phase I Radioimmunotherapy Trial Evaluating 90yttrium-Labeled Anti-Carcinoembryonic Antigen (CEA) Chimeric T84.66 in Patients with Metastatic CEA-Producing Malignancies.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 6, no. 10, Oct. 2000, pp. 3855–63. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=11051230&authtype=sso&custid=ns315887.

APA

Wong JYC, Chu, D. Z., Yamauchi, D. M., Williams, L. E., Liu, A., Wilczynski, S., Wu, A. M., Shively, J. E., Doroshow, J. H., & Raubitschek, A. A. (2000). A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 6(10), 3855–3863.

Chicago

Wong JYC, D Z Chu, D M Yamauchi, L E Williams, A Liu, S Wilczynski, A M Wu, J E Shively, J H Doroshow, and A A Raubitschek. 2000. “A Phase I Radioimmunotherapy Trial Evaluating 90yttrium-Labeled Anti-Carcinoembryonic Antigen (CEA) Chimeric T84.66 in Patients with Metastatic CEA-Producing Malignancies.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 6 (10): 3855–63. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=11051230&authtype=sso&custid=ns315887.